Karen J. Wernli, PhD

Wernli_Karen__205x293.jpg

“I consider patients the core of my research.”

Karen J. Wernli, PhD

Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute
Professor, Department of Health System Science, Kaiser Permanente Bernard J. Tyson School of Medicine
Affiliate Professor, Department of Epidemiology and Department of Health Systems and Population Health, University of Washington

Karen.J.Wernli@kp.org
206-287-2934
Twitter: @wernlikarenj

Biography

Karen Wernli, PhD, is a cancer epidemiologist and health services researcher whose work focuses on incorporating patient-centered outcomes to improve cancer care along the cancer care continuum, from prevention to survivorship. Her works spans several types of cancer, including lung, breast, and colorectal, and also explores the impact of cancer in special populations, such as adolescents and young adults. Her research strives to answer critical questions at the confluence of patients’ needs and clinical priorities. Overall, her research has resulted in approximately $30 million in research funding as principal investigator (PI) or site PI, more than 125 peer-reviewed publications (h-index 35), and more than 85 presentations at national conferences, symposia, and other public venues.

Dr. Wernli is a leader in multilevel intervention studies to improve lung cancer screening. She is currently conducting a pragmatic clinical trial funded by the National Cancer Institute (NCI) to test 2 multilevel interventions to improve adherence to annual lung cancer screening at Kaiser Permanente Washington (R01CA262015). Study interventions were developed using a mixed-methods approach — including patient and stakeholder engagement and human-centered design methods — to determine gaps for interventions, relevant features of interventions, and design concepts. Further, Dr. Wernli is also leading a pilot grant from the Alliance for Clinical Trials in Oncology to develop interventions to improve timely follow-up after a positive lung cancer screening scan. She is cancer care delivery research lead for the Kaiser Permanente Washington NCI Community Oncology Research Program (NCORP).

Dr. Wernli is a leader in the use of breast imaging in women with prior breast cancer, including in the use of breast magnetic resonance imaging (MRI). Dr. Wernli recently completed a Patient-Centered Outcomes Research Institute (PCORI) project that compared breast MRI to mammography for women already treated for breast cancer. Called Surveillance Imaging Modalities for Breast Cancer Assessment (SIMBA), the study used data from the Breast Cancer Surveillance Consortium (BCSC) and engaged patients and stakeholders to determine the best information for patient and physician decision-making. Dr. Wernli’s team translated that information into a new decision aid for breast cancer survivors. PCORI has recognized this work nationally and pointed to SIMBA as a model for effective patient engagement.

Dr. Wernli’s other breast cancer projects include collaborating with Natasha Stout, PhD, from Harvard University on an NCI-funded study to examine trends and outcomes related to the mandatory notification of breast density that has been enacted in many states. She also led research to determine temporal trends in the use of breast MRI over 10 years, based on indication for the scans. The analysis relied on national claims-based data across all 50 states.

Dr. Wernli is leading patient-centered research in adolescent and young adult (AYA) populations. She is a project co-lead with Kaiser Permanente Southern California researcher Erin Hahn, PhD, MPH, and Veterans Affairs researcher Neetu Chawla, PhD, MPH, in an NCI-funded project to evaluate health service utilization in early survivorship for AYA populations. The research is intended to identify multilevel gaps in health care utilization in AYA early-cancer survivors for forthcoming interventions. Previously, Dr. Wernli launched the Clare Project with KPWHRI researchers, including Marlaine Figueroa Gray, PhD, to understand patient, caregiver, and provider perspectives regarding medical decision-making for patients with advanced cancer. Using novel methods, all perspectives were garnered through social media recruitment. With NCI-funding, she has evaluated temporal trends and regional variation in end-of-life care in AYA cancer populations using national claims-based data.

Finally, Dr. Wernli is expanding her research expertise in clinical research studies beyond oncology clinical trials. She is principal investigator of a multisite study of flu and COVID-19 vaccine effectiveness funded by the Centers for Disease Control and Prevention from 2022 to 2027. Her study team is annually enrolling about 1,200 participants with flu-like symptoms into her research.

Dr. Wernli is a member of the American Society for Preventive Oncology, the Society for Epidemiologic Research, the American Society for Clinical Oncology, and the American Association for Cancer Research. She is an affiliate professor of epidemiology and health systems and population health at the University of Washington and a professor of health system science at the Kaiser Permanente Bernard J. Tyson School of Medicine.

Research interests and experience

  • Cancer

    Breast, lung, colorectal, ovarian, skin, and endometrial cancer; screening and surveillance; survivorship; patient-centered care; biostatistics; low-dose CT (LDCT); mammography; surveillance imaging; breast magnetic resonance imaging (MRI); systematic reviews; multilevel intervention studies; pragmatic clinical trials

  • Health Services & Economics

    Comparative effectiveness research, health outcomes research, patient-centered outcomes, health care quality, implementation science

    Preventive Medicine

    Cancer screening and surveillance

  • Patient-Centeredness

    Patient engagement, stakeholder engagement, qualitative research methods, mixed-methods, human-centered design

  • Vaccines & Infectious Diseases

  • Aging & Geriatrics

Recent publications

Ho TH, Bissell MCS, Lee CI, Lee JM, Sprague BL, Tosteson ANA, Wernli KJ, Henderson LM, Kerlikowske K, Miglioretti DL. Prioritizing screening mammograms for immediate interpretation and diagnostic evaluation based on risk of recall. J Am Coll Radiol. 2023 Mar;20(3):299-310. doi: 10.1016/j.jacr.2022.09.030. Epub 2022 Oct 20. PubMed

Kim SS, Chung JR, Talbot HK, Grijalva CG, Wernli KJ, Kiniry E, Martin ET, Monto AS, Belongia EA, McLean HQ, Gaglani M, Mamawala M, Nowalk MP, Moehling Geffel K, Tartof SY, Florea A, Lee JS, Tenforde MW, Patel MM, Flannery B; Strain Surveillance and Emerging Variants Team; Bentz ML, Burgin A, Burroughs M, Davis ML, Howard D, Lacek K, Madden JC, Nobles S, Padilla J, Sheth M. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022. Influenza Other Respir Viruses. 2022 Nov;16(6):975-985. doi: 10.1111/irv.13029. Epub 2022 Jul 29. PubMed

Holman A, Kross E, Crothers K, Cole A, Wernli K, Triplette M. Patient perspectives on longitudinal adherence to lung cancer screening. Chest. 2022 Jul;162(1):230-241. doi: 10.1016/j.chest.2022.01.054. Epub 2022 Feb 8. PubMed

Wernli KJ, Smith RE, Henderson LM, Zhao W, Durham DD, Schifferdecker K, Kaplan C, Buist DSM, Kerlikowske K, Miglioretti DL, Onega T, Alsheik NH, Sprague BL, Jackson-Nefertiti G, Budesky J, Johnson D, Tosteson ANA. Decision quality and regret with treatment decisions in women with breast cancer: pre-operative breast MRI and breast density. Breast Cancer Res Treat. 2022 Aug;194(3):607-616. doi: 10.1007/s10549-022-06648-7. Epub 2022 Jun 20. PubMed

Li ZN, Liu F, Jefferson S, Horner L, Carney P, Johnson MDL, King JP, Martin ET, Zimmerman RK, Wernli K, Gaglani M, Thompson M, Flannery B, Stevens J, Tumpey T, Levine MZ. Multiplex detection of antibody landscapes to SARS-CoV-2/influenza/common human coronaviruses following vaccination or infection with SARS-CoV-2 and influenza. Clin Infect Dis. 2022 Jun 10:ciac472. doi: 10.1093/cid/ciac472. Online ahead of print. PubMed

Lowry KP, Callaway KA, Lee JM, Zhang F, Ross-Degnan D, Wharam JF, Kerlikowske K, Wernli KJ, Kurian AW, Henderson LM, Stout NK. Trends in annual surveillance mammography participation among breast cancer survivors from 2004 to 2016.  J Natl Compr Canc Netw. 2022;20(4):379-386.e9. doi: 10.6004/jnccn.2021.7081.  PubMed

Smith RE, Sprague B, Henderson LM, Kerlikowske K, Miglioretti DL, Buist DSM, Wernli KJ, Onega T, Schifferdecker K, Jackson-Nefertiti G, Johnson D, Budesky J, Tosteson ANA. Breast density knowledge in a screening mammography population exposed to density notification. J Am Coll Radiol. 2022 Mar 24:S1546-1440(22)00248-4. doi: 10.1016/j.jacr.2022.02.025 [Epub ahead of print] PubMed

Chung JR, Kim SS, Kondor RJ, Smith C, Budd AP, Tartof SY, Florea A, Talbot HK, Grijalva CG, Wernli KJ, Phillips CH, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Reis M, Moehling Geffel K, Nowalk MP, DaSilva J, Keong LM, Stark TJ, Barnes JR, Wentworth DE, Brammer L, Burns E, Fry AM, Patel MM, Flannery BF. Interim estimates of 2021-22 seasonal influenza vaccine effectiveness - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):365-370. doi: 10.15585/mmwr.mm7110a1. PubMed

Haas CB, Hsu L, Lampe JW, Wernli KJ, Lindström S. Cross-ancestry genome-wide association studies of sex hormone concentrations in pre- and postmenopausal women. Endocrinology. 2022 Feb 22:bqac020. doi: 10.1210/endocr/bqac020. Online ahead of print. PubMed

Schousboe JT, Sprague BL, Abraham L, O'Meara ES, Onega T, Advani S, Henderson LM, Wernli KJ, Zhang D, Miglioretti DL, Braithwaite D, Kerlikowske K. Cost-effectiveness of screening mammography beyond age 75 years: a cost-effectiveness analysis. Ann Intern Med. 2022 Jan;175(1):11-19. doi: 10.7326/M20-8076. Epub 2021 Nov 23. PubMed

 

Research

FluVE_story_image_1col.jpg

KPWHRI contributes to flu vaccine effectiveness results

Interim data for the 2023-2024 flu season shows that the vaccine has protected all age groups.

Research

Cancer-prevention-story_1col.jpg

Improving cancer prevention and early detection

How KPWHRI is contributing to better cancer screening and better outcomes for patients.

News

Flu-VE-study_1col.jpg

KPWHRI begins new phase of flu surveillance

KPWHRI receives $10 million to continue vaccine effectiveness research for flu, COVID-19, and other respiratory diseases.

Research

illustration nurse and patient mammogram

Roundup of 3 recent studies on breast cancer screening

New research spotlights overdiagnosis, MRI before surgery, and a new way of predicting breast cancer risk

VOICE STUDY

Man sitting at table typing on computer

Understanding young adults’ experiences with cancer

The VOICE study aims to improve the health and health care of people who had cancer as adolescents and young adults.

Co-designing with patients

Human-Centered-Design-research_1col.jpg

Patient collaboration sparks care innovations

By partnering with patients, KPWHRI researchers developed 2 new interventions to boost lung cancer screening.